Dianthus Therapeutics, Inc. $DNTH Stock Holdings Lessened by Virtus Investment Advisers LLC

Virtus Investment Advisers LLC reduced its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 30.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,875 shares of the company’s stock after selling 2,111 shares during the quarter. Virtus Investment Advisers LLC’s holdings in Dianthus Therapeutics were worth $91,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DNTH. US Bancorp DE boosted its stake in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after buying an additional 1,510 shares during the period. AlphaQuest LLC purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth $94,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Invesco Ltd. grew its stake in Dianthus Therapeutics by 38.7% in the first quarter. Invesco Ltd. now owns 15,978 shares of the company’s stock valued at $290,000 after purchasing an additional 4,457 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its position in Dianthus Therapeutics by 3.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock worth $332,000 after purchasing an additional 602 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Raymond James Financial reiterated an “outperform” rating and set a $63.00 price target (up from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. HC Wainwright lifted their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Robert W. Baird boosted their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 9th. Guggenheim raised their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Finally, Truist Financial started coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 14th. They issued a “buy” rating and a $56.00 price objective for the company. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $63.43.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 109,031 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This trade represents a 96.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 216,538 shares of company stock worth $8,079,575 over the last quarter. 16.56% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Trading Down 0.1%

Shares of Dianthus Therapeutics stock opened at $43.98 on Monday. The firm has a fifty day simple moving average of $37.05 and a 200-day simple moving average of $27.23. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -12.64 and a beta of 1.56. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $44.95.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. As a group, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.